Business Context and Reporting Period
This Form 8-K was filed by Supernus Pharmaceuticals, Inc. on August 28, 2012. The report details modifications to the compensatory arrangements of the Company's executive officers following the completion of its recent initial public offering (IPO).
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation adjustments.
Material Changes
The Compensation Committee approved increases to the annual base salaries of six executive officers, effective September 1, 2012. The specific adjustments are as follows:
- Jack A. Khattar (President and CEO): Increased from $432,786 to $450,000.
- Gregory S. Patrick (VP and CFO): Increased from $265,000 to $300,000.
- Stefan K.F. Schwabe, MD, Ph.D. (EVP and CMO): Increased from $320,000 to $330,000.
- Padmanabh P. Bhatt, Ph.D. (SVP, IP and CSO): Increased from $290,884 to $306,000.
- Jones W. Bryan, Ph.D. (VP of Business Development): Increased from $223,364 to $250,000.
- Tami T. Martin, R.N., Esq. (VP of Regulatory Affairs): Increased from $221,095 to $240,000.
The filing states that all other terms and conditions of the compensatory arrangements remain unchanged.
Outlook and Management Commentary
Management commentary indicates that these salary increases were the result of a Compensation Committee review intended to align executive base salaries with those of other public companies in the pharmaceutical industry following the IPO. The filing does not provide specific guidance, risk factors, or contingencies beyond the context of this compensation adjustment.
Investor Verification Points
- Verify the effective date of the salary increases (September 1, 2012).
- Confirm that no other terms of the executive compensation agreements were altered.
- Review the Company's most recent 10-K or 10-Q for baseline financial performance data, as this 8-K contains none.